Corporate venture capital is reshaping how biopharma companies get funded, with investors emphasizing “permanent capital” and strategic capabilities. Reporting highlights a British Business Bank £75 million commitment to Molten Ventures’ new Growth Fund, designed to help UK and European technology firms reach Series B and beyond. The article also cites panel comments that corporate investors are becoming standard: about 70% of US biopharma companies that went public since 2022 had a corporate investor on the cap table, and 60% of pharma acquisitions involved companies with corporate investors. For biotech founders and CEOs, the central operational change is governance and ownership strategy—how corporate investors participate can differ from traditional VC, including approaches that avoid syndicates in favor of more direct partnership. Overall, the update reflects a funding “plumbing” shift that could affect everything from trial capital continuity to partnership expectations during commercialization planning.